Femasys announced that it has activated enrollment for its pivotal FemBloc trial at Stanford Medicine in Palo Alto, California. The FemBloc Intratubal Occlusion for TranscervicAL Permanent Birth Control is being conducted to investigate the safety and efficacy of its investigational permanent birth control candidate, FemBloc. The FDA-approved, multi-center trial is designed to address the high unmet need that exists for women seeking permanent birth control, for whom elective surgery currently remains the only option. “We are thrilled to include Stanford amongst the clinical trial sites participating in this initial phase of the FINALE trial, as we have partnered with Doctors Blumenthal and Cahill in earlier FemBloc studies,” said Kathy Lee-Sepsick, founder, president and chief executive officer of Femasys. “Dr. Blumenthal, a leader in the field of gynecology, has dedicated his career to advancing research and bringing women’s health technologies to those in need around the globe. We greatly appreciate his long-standing support of FemBloc and the selection of Dr. Cahill as the principal investigator in the FINALE trial, as we continue to work together to progress this much needed non-surgical permanent birth control option for women.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on FEMY:
- Femasys files to sell 18.11M shares of common stock for holders
- Femasys Inc. Announces the Appointment of James Liu, M.D., as Chief Medical Officer
- Femasys appoints James Liu as Chief Medical Officer
- Femasys Inc. Completes Enrollment of FemaSeed Pivotal Trial in Support of Commercial Launch
- Femasys completes enrollment of FemaSeed pivotal trial